medigraphic.com
ISSN 1561-3119 (Electronic)

2021, Number 1

<< Back Next >>

Rev Cubana Pediatr 2021; 93 (1)

New biotherapeutics: next-generation probiotics

Castañeda GC

Language: Spanish
References: 36
Page: 1-20
PDF size: 912.77 Kb.


ABSTRACT

Introduction: Next-generation probiotics are novel active biotherapy that has emerged over the past decade based on unknown commensal bacteria, isolated by molecular biology methods and representing a new challenge to be used in specific conditions related to severe alterations of dysbiosis in the gut microbiota.
Objective: Analyze the characteristics of next generation probiotic candidates due to their mechanisms of action and the value of their application for the treatment of specific metabolic and systemic conditions.
Methods: Publications from January 2010 to July 2020 in Spanish and English were reviewed on PubMed, Scimago, ScIELO, and were used the terms: next generation probiotics, probiotics, gut microbiota, dysbiosis.
Results: There were updated criteria on next-generation probiotics, concept, mechanisms of action, specificities, results of research in mice and limited human studies in specific systemic diseases and metabolic syndromes, such as obesity, type 2 diabetes mellitus, inflammatory bowel diseases and cancer. Historical background, indications such as biotherapeutics in bowel diseases and next-generation probiotic differential traits with traditional probiotics were reviewed.
Final Considerations: Knowledge gained over the past decade in studies with non-previously isolated intestinal commensal bacteria emerges as next-generation probiotics for active biotherapy as the treatment of choice in severe intestinal microbiota dysbiosis alterations, associated with specific systemic diseases that lead to metabolic syndrome. Experimental evidence opens up promising path to influence improvement or resolution of such conditions.


REFERENCES

  1. RiberaCasado JM. Centenario de Elie Metchnikoff (1845-1916). Edu Méd. 2017 [acceso 30/07/2020];18(2):136-43. Disponible en: https://medes.com/publication/120720

  2. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. El proyecto del microbioma humano. Nature. 2007 [acceso 02/03/2020];449:804-11. Disponible en: https://medes.com/publication/120720

  3. Brinda S, Hill C, Johansen E, Obis D, Pot B, Sanders ME, et al. Criteria tp qualify microorganisms as "Probiotics" in foods and dietary supplements. Front Microb 2020 [acceso 04/08/2020]. Disponible en: https://www.frontiersin.org/articles/10.3389/fmicb.2020.01662/full

  4. van den Akker C HP, van Goudoever JB, Raanan S, Domellöf M, Embleton ND, Hojsak Iva,| et al. Probiotics and preterm infants. A position paper by the ESPGHAN Committee on Nutrition and the ESPGHAN Working Group for Probiotics and Prebiotics. J Ped Gastroenterol Nutr. 2020 [acceso 03/08/2020];70(5):664-80. Disponible en: https://journals.lww.com/jpgn/Abstract/publishahead/Probiotics_and_Preterm_Infants__A_Position_Paper.96178.aspx

  5. O'Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol 2017 [acceso 30/07/2020];2:17057. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28440276/

  6. Lilly DM, Stillwell RH. Probiotic growth promoting factors produced by microorganisms. Science 1965 [acceso 02/08/2020];147(3659):747-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14242024/

  7. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document of Internat Scientific Association Probiotics Prebiotics consensus statement on the scope and appropiate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 [acceso 04/08/2020];1:506-14. Disponible en: https://www.nature.com/articles/nrgastro.2014.66

  8. Food and Agricultural Organization of the United Nations and World Health Organization. Health and nutritional properties of probiotics in food including power milk with livel acetic acid bacteria. Washington, D. C.: OMS; 2001[acceso 04/08/2020]. Disponible en: http://www.fao.org/3/a-a0512e.pd

  9. Martín R, Langella P. Emerging Health Concepts in the Probiotics Field: Streamlining the Definitions. Front Microbiol. 2019 [acceso 04/08/2020]10:3389. Disponible en: https://www.frontiersin.org/articles/10.3389/fmicb.2019.01047/full

  10. Castañeda C. Probióticos. Puesta al día. Rev Cubana Pediatr. 2018 [acceso 04/08/2020];90(2):286-98. Disponible en: http://scielo.sld.cu/pdf/ped/v90n2/ped09218.pdf

  11. Shanahan F. Therapeutic implications of manipulating and mining the microbiota. J. Physiol. 2009 [acceso 18/08/2020];587:4175-9. Disponible en: https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/jphysiol.2009.174649

  12. Guarner F, Sanders ME, Eliakim R Khan AG, Fedorak R, Gangl A, Garich J et al. Probiotics and prebiotics. Global Guidelines. EE. UU.: World Gastroenterol Organization; 2011-2017 [acceso 06/08/2020]. Disponible en: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-spanish-2017.pdf

  13. Martinelli M, Banderali G, Bobbio M, Civardi E, Chiara A, D'Elios S, et al. Probiotics efficacy in paediatric diseases: Which is the evidence? A critical review on behalf of the Italian Society of Pediatrics. Ital J Pediatr. 2020 [acceso 02/09/2020];46(1):104. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430011/

  14. Castañeda C. Probiótico Saccharomyces boulardii CNCM I-745: de la investigación a la práctica clínica. Belice J Med. 2017 [acceso 14/08/2020];6(2):15-21. Disponible en: https://pdfs.semanticscholar.org/bd2e/4e808a392980ea1170463b9f00f2ac392a16.pdf

  15. Chang CJ, Lin TL, Tsai YL, Wu TR, Lai WF, Lu CC, et al. Next generation probiotics in disease amelioration. J Food Drug Anal.2019 [acceso 03/08/2020];27(3):615-2. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31324278/

  16. Langella P, Guarner F, Martin R [editorial]. Next Generation Probiotics: From commensal bacteria to novel drugs and food supplements. Front Microbiol. 2019 [acceso 05/08/2020];10:1973. Disponible en: https://www.frontiersin.org/articles/10.3389/fmicb.2019.01973/full

  17. Lin T-Z, Shu C-C, Lai W-F, Tzeng C-M, Lai H-C, Lu C-C. Investiture of next generation probiotics on amelioration of diseases - Strains do matter. Med Microecol. 2019 [acceso 03/09/2020];1-2:100002. Disponible en: https://www.sciencedirect.com/science/article/pii/S2590097819300023

  18. Castañeda C. Probióticos de Nueva Generación. Belice J Med. 2019 [acceso 10/08/2020];8(2):26-32. Disponible en: https://62320b92-5ad1-4eb3-9daa-12e6ad9b1861.filesusr.com/ugd/fd7ee3_01c93609a0264600871108b20c2936c9.pdf

  19. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016 [acceso 21/08/2020];65:426-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26100928/

  20. Rodríguez-Carrio J, Salazar N, Margolles A, González S, Gueimonde M, de los Reyes-Gavilán C.G, et al. Free fatty acids profiles are related to gut microbiota signatures and short-chain fatty acids. Front Immunol. 2017 [acceso 28/07/2020];823. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2017.00823/full

  21. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, at al. A purified membrane protein from Akkermansia muciniphila or the pauteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017 [acceso 23/07/2020];23:107-13. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27892954/

  22. Cani PD, de Vos WM. Next-Generation beneficial microbes: The case of Akkermansia municiphila Front Microbiol. 2017 [acceso 22/08/2020];8:1765. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29018410/Akkermansiamuniciphila

  23. Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front Microbiol. 2020 [acceso 21/08/2020];11:219. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32153527/

  24. Shin J, Noh J-R, Chang D-H, Kim Y-H, Kim MH, Lee ES, et al. Elucidation of Akkermansia muciniphila Probiotic Traits Driven by Mucin Depletion. Front. Microbiol. 2019 [acceso 22/08/2020];10:1137. Disponible en: https://www.frontiersin.org/articles/10.3389/fmicb.2019.01137/full

  25. Martín R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, et al. Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol. 2017 [acceso 20/06/2020];8:1226. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28713353/

  26. Breyner NM, Michon C, de Sousa CS, Vilas Boas PB, Chain F, Azevedo VA, et al. Microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii shows a protective effecton DNBS and DSS-induced colitis model in mice through inhibition of NF-?Bpathway. Front. Microbiol. 2017 [acceso 20/08/2020];8:114. Disponible en: https://www.frontiersin.org/articles/10.3389/fmicb.2017.00114/full

  27. Quévrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut. 2016 2017 [acceso 24/08/2020];65:415-425. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26045134/

  28. El Hage R, Hernández-Sanabria E, Van de Wiele T. Emerging Trends "Smart Probiotics": Functional Consideration for the Development of Novel Health and Industrial Applications. Front Microbiol. 2017 [acceso 22/08/2020];8:1889. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29033923/

  29. Engels C, Ruscheweyh H-J, Beerenwinkel N, Lacroix C, Schwab C. The common gut microbe Eubacteriumhallii also contributes to intestinal propionate formation. Front Microbiol. 2016 [acceso 21/08/2020];7:713. Disponible en: https://www.frontiersin.org/articles/10.3389/fmicb.2016.00713/full

  30. Udayappan S, Manneras-Holm L, Chaplin-Scott A, Belzer C, Herrema H, Dallinga-Thie G-M, et al. Oral treatment with Eubacteriumhallii improves insulin sensitivity in db/dbmice. NPJ Biofilms Microbiom. 2016 [acceso 24/08/2020];2:16009. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515273/

  31. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013 [acceso 23/08/2020];500:232-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23842501/

  32. Pandiyan P, Bhaskaran N, Zou M, Schneider E, Jayaraman S,Huehn J. Microbiome Dependent Regulation of Tregs and Th17 Cells in Mucosa. Front. Immunol. 2019 [acceso 23/08/2020];10:426. Disponible en: htpps:://www.frontiersin.org/articles/10.3389/fimmu.2019.00426/full

  33. Fernández-Murga ML, Sanz Y. Safety assessment of Bacteroides uniformis CECT 7771 isolated from stools of healthy breast-fed infants. Plos One. 2016 [acceso 17/08/2010);11:e0145503. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145503

  34. Yang J-Y, Lee Y-S, Kim Y, Lee S-H, Ryu, S, Fukuda S, et al. Gut Commensal Bacteroidesacidifaciens prevents obesity and improves insulin sensitivity in mice. Mucosal Immunol. 2016 [acceso 18/08/2020];10:104-16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27118489/

  35. Castañeda C. Gut Dysbiosis. EC Gastroenterol Digestive System. 2020 [acceso 10/08/2020];7(3):1-4. Disponible en: https://www.ecronicon.com/ecgds/pdf/ECGDS-07-00528.pdf

  36. Langella P. Next-generation probiotics to prevent and treat inflammatory bowel disease. In: Intestinal microbiota and its host: harmony or discord? Colloquium 2018. Francia: L'Institut Servier Scientific; 2018. [acceso 10/08/2010). Disponible en: https://institut-servier.com/sites/default/files/publications-en/P_Langella_EN.pdf




2020     |     www.medigraphic.com